Welcome

Expert perspectives on the future of cancer research and care, including the latest on CAR T-cell therapy, Big Data management, and international partnerships, are among the highlights of the 2018 joint annual meeting of the Association of American Cancer Institutes (AACI) and the Cancer Center Administrators Forum (CCAF).

The meeting convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies. The three-day event focuses on exploring solutions to common challenges and sharing best practices.

This year’s meeting will mark two major leadership transitions for AACI. Roy A. Jensen, MD, director of The University of Kansas Cancer Center, will become the association’s new president and will introduce his presidential initiative, which aims to develop a comprehensive, cancer-specific clearinghouse of model legislation for AACI cancer centers to share with their state legislators. In addition, this will be my final annual meeting as I will be retiring later this month after 19 years as AACI’s first executive director. Jennifer W. Pegher, who has served for six years at AACI as director of government relations and deputy director, will succeed me as AACI’s new executive director.

This year’s annual meeting program, jointly formulated by AACI and CCAF, begins with a panel discussion by four distinguished cancer center leaders who will share their insights and predictions for how academic cancer centers will evolve over the next decade. Special guests include Ned Sharpless, MD, who will be addressing the annual meeting for the first time as director of the National Cancer Institute. Awardees this year are Charles M. Perou, MD, who will receive the AACI Distinguished Scientist Award, and Richard and Susan Rogel, who will be honored with AACI’s first Champion for Cures Award for their transformational philanthropy at the University of Michigan Rogel Cancer Center.

No other event provides information on cancer research and patient care issues as they pertain to academic cancer center leaders, and provides them with a forum to discuss common issues. On behalf of the 2018 AACI/CCAF Annual Meeting Program Committee, welcome to the Windy City!

Sincerely,
Barbara Duffy Stewart, MPH
AACI Executive Director
Program Committee

Chair: Randall F. Holcombe, MD, MBA
University of Hawai‘i Cancer Center
University of Hawai‘i at Mānoa

Michael J. Bertram, PhD, MBA
UAB Comprehensive Cancer Center
University of Alabama at Birmingham

Peter Connor, MS
University of Wisconsin
Carbone Cancer Center

B. Mark Evers, MD
UK Markey Cancer Center

Seanne Falconer, MBA, FACHE
Masonic Cancer Center
University of Minnesota

Stanton L. Gerson, MD
Case Comprehensive Cancer Center

Roy A. Jensen, MD
The University of Kansas Cancer Center

Candace S. Johnson, PhD
Roswell Park Comprehensive Cancer Center

Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center at Jefferson Health

Carrie Lee, MD, MPH
UNC Lineberger
Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Malcolm Moore, MD
BC Cancer

Timothy L. Ratliff, PhD
Purdue University
Center for Cancer Research

Thomas A. Sellers, PhD, MPH
Moffitt Cancer Center

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Agenda

All sessions will be held in the Wright Ballroom, Lobby Level, except where indicated.

Sunday, September 30

11:00 am Meeting Registration Begins
Wright Foyer, Lobby Level

11:00 am Exhibits Open
Wright Foyer, Lobby Level

12:00 pm Welcome and AACI Business Meeting
President’s Report
Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Executive Director’s Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer’s Report
Mr. Jeff Walker
City of Hope National Medical Center

Program Chair’s Report
Dr. Randall F. Holcombe
University of Hawai‘i Cancer Center
University of Hawai‘i at Mānoa

CCAF Report
Mr. David M. Gosky
UK Markey Cancer Center

1:00 pm A 10-Year Outlook for Academic Cancer Centers
Academic cancer centers have made remarkable strides in recent years that have enhanced their ability to deliver better care to patients, from the increased availability of genomic information sequencing to advances in the areas of targeted therapy, immunotherapy, and cancer screening technology. To help centers sustain that progress and build on their decades of learning, speakers in this session will share their perspectives and predictions for how academic cancer centers will evolve over the next 10 years. Topics of conversation will include maintaining research and managing innovation; distributed care; changes in reimbursement and points of care; and use of electronic methods of care delivery.

All 2018 AACI/CCAF Annual Meeting sessions will be held in the Wright Ballroom, Lobby Level, except where indicated.
Agenda

Sunday, September 30

4:00 – 6:00 pm  
6th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting  
Avoiding Physician Burnout: Strategies for Promoting Personal and Professional Satisfaction  
Whether diagnosing cancer or managing related complications, devising personalized treatment plans, providing critical support in the face of daunting illness, or myriad other intellectually and emotionally stimulating tasks, caring for cancer patients can be immensely rewarding. Despite its rewards, caring for cancer patients can also be a stressful calling. From life and death decision-making to keeping pace with constantly evolving science, productivity requirements, and regulatory and administrative burdens, oncology practice takes its toll physically and emotionally. In this session, panelists will discuss the professional and personal consequences associated with physician burnout and will suggest strategies for avoiding downturns and promoting personal and professional satisfaction.  
Moderator: Dr. Randall F. Holcombe  
University of Hawai‘i Cancer Center  
University of Hawai‘i at Mānoa  
Dr. Fay J. Hlubocky  
The University of Chicago Medicine Comprehensive Cancer Center  
Dr. Daniel McFarland  
Memorial Sloan Kettering Cancer Center  
Dr. Ronald M. Epstein  
Wilmot Cancer Institute  
University of Rochester Medical Center

2:00 pm  
New President’s Initiative  
Dr. Roy A. Jensen  
The University of Kansas Cancer Center

2:15 pm  
Networking Break

2:45 pm  
Cancer is a Global Issue: Partnerships with the Developing World  
A growing number of cancer centers have established partnerships with countries in the developing world, with involvement extending to both research and the direct delivery of care. This session will include an overview of cancer research and treatment in the developing world, as well as details about how centers are interacting with specific countries including Kenya, Malawi, and Cuba, where U.S. sanctions are creating unique challenges for cancer research collaborations.  
Moderator: Dr. Malcolm Moore  
BC Cancer  
Dr. Jack Welch  
National Cancer Institute  
Dr. Satish Gopal  
UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill  
Dr. Dan Namarika  
Ministry of Health, Malawi  
Dr. Patrick J. Loehrer  
Indiana University Melvin & Bren Simon Cancer Center  
Dr. Kelvin P. Lee  
Roswell Park Comprehensive Cancer Center

4:30 – 5:30 pm  
CCAF Business Meeting  
(closed session for members of CCAF)  
Sullivan Ballroom A, Lobby Level

6:00 – 7:30 pm  
Welcome Reception — Sponsored by Forte  
Garden Terrace, Third Floor

Program Subject to Change
Agenda

Monday, October 1

7:00 am  General Breakfast  
Sullivan Ballroom BC, Lobby Level

7:00 am  Exhibits Open  
Wright Foyer, Lobby Level

8:00 am  AACI Presidential Initiative Update: Network Care  
Managing cancer center networks is a complex task involving many moving parts; without a clear roadmap, a network can become unmanageable. AACI’s Network Care Initiative aims to help AACI’s academic cancer centers paint an accurate picture of their impact on cancer care across the regions they serve. AACI President Dr. Stanton Gerson will provide an update on the initiative, including a summary of final survey results. This session will cover topics related to network management, including standardization of care and the use of care paths (suggested diagnostic and treatment pathways); collaborating with other centers and community sites; working with varied employment network models; and providing access to clinical trials.  

Moderator: Dr. Stanton L. Gerson  
Case Comprehensive Cancer Center  
Dr. Michael E. Kupferman  
University of Texas MD Anderson Cancer Center  
Dr. Ravi Salgia  
City of Hope Comprehensive Cancer Center

8:45 am  Concurrent Session  
How to Get the Most Out of Your External Advisory Board (EAB)  
Wright Ballroom, Lobby Level  

When immersed in the day-to-day challenges of managing a cancer center, it can be easy to develop tunnel vision and lose sight of the big picture. A fresh perspective can help identify areas for improvement that may have been overlooked. As part of the CCSG renewal process, National Cancer Institute (NCI)-Designated Cancer Centers are required to host site visits and demonstrate success in carrying out meritorious science. To prepare for renewal, cancer centers invite external advisory boards (EAB) to visit their cancer centers and provide detailed critiques. In this session, panelists will discuss best practices for selecting and inviting experts to join a cancer center’s EAB, how to set expectations before a site visit, and the unique ways AACI cancer centers utilize this essential resource.  

Moderator: Mr. Peter Connor  
University of Wisconsin Carbone Cancer Center  
Dr. Karen Knudsen  
Sidney Kimmel Cancer Center at Jefferson Health  
Ms. Lauren Hackett  
Vanderbilt-Ingram Cancer Center  
Dr. Michelle M. Le Beau  
The University of Chicago Medicine Comprehensive Cancer Center  
Mr. David M. Gosky  
UK Markey Cancer Center

8:45 am  Concurrent Session  
Big Data in Cancer Care  
Sullivan Ballroom, Lobby Level  

As Big Data changes the face of cancer research and treatment, the vast amount of information—and wide variety of sources for that information—are presenting significant challenges in collecting and integrating data. This session convenes commercial and academic players in the Big Data arena with an eye toward enhancing dialogue and developing stronger linkages that could lead to expanded information-sharing and improved patient care.  

Moderator: Dr. Thomas A. Sellers  
Moffitt Cancer Center  
Ms. Cindy Terrano  
Moffitt Cancer Center  
Dr. Kerin Adelson  
Yale Cancer Center  
Yale School of Medicine  
Dr. John Sweetenham  
Huntsman Cancer Institute  
University of Utah

10:00 am  Break
Monday, October 1 continued

10:15 am  Cancer Health Economics
In the face of persistent shifts in the political landscape and health care marketplace, cancer centers are confronting an expanding array of funding and reimbursement challenges. Speakers in this session will discuss emergent issues such as understanding policies governing coverage for gathering genomic sequencing data and other innovative therapies, caring for underserved patients, and the latest developments at the Centers for Medicare and Medicaid Services.

Moderator: Dr. Randall F. Holcombe
University of Hawai‘i Cancer Center
University of Hawai‘i at Mānoa
Dr. K. Robin Yabroff
American Cancer Society
Dr. Stuart Peacock
BC Cancer
Dr. Rena M. Conti
Boston University Questrom School of Business

11:30 am  2018 AACI Distinguished Scientist Award
Quantitative Medicine for Breast Cancer Patients
Charles M. Perou, PhD, a renowned breast cancer researcher at the UNC Lineberger Comprehensive Cancer Center, is being recognized by AACI for his accomplishments in the field of precision medicine and for groundbreaking research in the characterization of the diversity of human tumors. The clinical value of his work leading to the discovery of the intrinsic subtypes of breast cancer has had a profound impact on the treatment of breast cancer patients worldwide. Dr. Perou’s talk will focus on sequencing studies for gene expression analysis; specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers.

Dr. Charles M. Perou
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

12:30 pm  AACI Awards Lunch
Sullivan Ballroom, Lobby Level
2018 AACI Champion for Cures Award
Richard and Susan Rogel

1:30 pm  Networking, CRI Posters, and Dessert — Sponsored by Florence
Wright Foyer, Lobby Level

2:00 pm  2018 Election Update
(session not CME accredited)
With the 2018 election just weeks away, Mr. Frommer will discuss the midterm elections, highlighting retirements and toss-ups and the impact the winners might have on cancer centers. He will also discuss the prospects for funding for the NIH in this and the next Congress.

Mr. Ross A. Frommer
Columbia University Irving Medical Center

2:15 pm  AACI Clinical Research Initiative (CRI) Update
In July, AACI’s CRI convened its 10th annual meeting with the program theme “Leveraging Change to Advance Cures for Cancer Patients.” The meeting provided an opportunity for clinical trials office (CTO) administrative and medical directors, representatives from industry, corporate roundtable members, and others to network, share best practices, and begin conversations that can lead to more effective cancer treatments. During this session, Dr. Lee will highlight CRI’s progress and growth over the past year—this year’s meeting drew a record 405 attendees and more than 60 poster submissions—as well as goals for 2019. She will also present preliminary results from the CRI benchmarking survey, which captured data on CTO workload, structure and staffing, trial activation timeline, and sources of CTO funding support at AACI cancer centers.

Dr. Carrie Lee
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

2:45 pm  Comprehensive Cancer Patient Support
Just as a spouse, children, relatives, and friends offer invaluable support to a loved one with cancer, cancer centers are increasingly recognizing the value to patients of a support network of experts drawn from fields as disparate as mental health, geriatric care, pain and symptom management, survivorship, and counseling for financially challenged patients. Over time, the field has transformed from palliative care and alternative medicine to an expansive array of research interests and treatment approaches that underpin nearly all cancer center operations. Panelists will explore programs that cancer centers have developed to enhance comprehensive support and deliver multidisciplinary care for the patient with cancer.

Moderator: Dr. Donald L. Rosenstein
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. Judith A. Paice
Robert H. Lurie Comprehensive Cancer Center
Northwestern University

Continued page 10
Monday, October 1 continued

Dr. Smita Bhatia  
UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

Dr. Steven R. Patierno  
Duke Cancer Institute  
Duke University Medical Center

4:00 pm  Break

4:15 pm  Concurrent Session  
CCSG Nuts and Bolts  
Wright Ballroom, Lobby Level

Optimal compliance with NCI Cancer Center Support Grant (CCSG) guidelines will be explored in this session, with particular focus on selected cancer centers that have recently completed core grant submissions. The practical implications of preparing a CCSG competing renewal will be reviewed, and advice will be offered regarding different approaches for freestanding versus matrix cancer centers.

Moderator: Mr. Alex Zafirovski  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

Ms. Donna Berrier  
Hollings Cancer Center  
Medical University of South Carolina

Mr. Dale Henry  
Roswell Park Comprehensive Cancer Center

Ms. Melissa Fitzmaurice Neligan  
UCLA Jonsson Comprehensive Cancer Center

4:15 pm  Concurrent Session  
Tumor Microenvironment  
Sullivan Ballroom, Lobby Level

The tumor microenvironment is a complex network of cells and extracellular matrix proteins that support tumor development and progression. As we move toward personalized medicine in cancer care, understanding the influence of structural entities on gene expression and communication among functionally distinct, but phenotypically identical, cells within the environment is essential to effectively translating individualized therapy to patients.

Moderator: Dr. B. Mark Evers  
UK Markey Cancer Center

Dr. Vadim Backman  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

Dr. Paul Robson  
The Jackson Laboratory Cancer Center

5:30 pm  Sessions End

8:30 – 11:00 pm  Hospitality Suite — Sponsored by Complion  
ETA Restaurant, Lobby Level

Tuesday, October 2

7:00 am  General Breakfast  
Sullivan Ballroom BC, Lobby Level

7:00 am  Topic-Specific Breakfast Roundtable Discussions  
Sullivan Ballroom A, Lobby Level

Advice For Your First CCSG  
Ms. Seanne Falconer  
Masonic Cancer Center  
University of Minnesota

Career Enhancement  
Dr. John Crispino  
Mr. Alex Zafirovski  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

Data Collection for Community Outreach and Engagement  
Dr. Michael J. Bertram  
UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

So You Want to be Designated?  
Mr. David M. Gosky  
UK Markey Cancer Center

Dr. Robert Mannel  
Stephenson Cancer Center  
University of Oklahoma
**Agenda**

**Tuesday, October 2 continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td><strong>Exhibits Open</strong>&lt;br&gt;Wright Foyer, Lobby Level</td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>NCI Director’s Report</strong>&lt;br&gt;The director of the NCI will highlight programmatic priorities and identify funding opportunities to support ongoing collaborations between the NCI and academic cancer centers.&lt;br&gt;&lt;br&gt;<strong>Dr. Norman E. Sharpless</strong>&lt;br&gt;National Cancer Institute</td>
</tr>
<tr>
<td>8:45 am</td>
<td><strong>Guidelines-Driven Review: Conveying Comprehensiveness, Training, and Community Engagement</strong>&lt;br&gt;As cancer centers continue to wrestle with revised guidelines for the NCI’s CCSG application, some metrics that help to determine funding levels are proving problematic. Panelists will discuss comprehensiveness, training, and community engagement, with an eye toward clarifying definitions, NCI’s perspective and expectations, and factors that drive the scoring of centers’ performance in these areas.&lt;br&gt;&lt;br&gt;<strong>Moderator: Dr. Roy A. Jensen</strong>&lt;br&gt;The University of Kansas Cancer Center&lt;br&gt;&lt;br&gt;<strong>Dr. Randall F. Holcombe</strong>&lt;br&gt;University of Hawai‘i Cancer Center&lt;br&gt;University of Hawai‘i at Mānoa&lt;br&gt;&lt;br&gt;<strong>Dr. Cory Abate-Shen</strong>&lt;br&gt;Herbert Irving Comprehensive Cancer Center&lt;br&gt;Columbia University Medical Center&lt;br&gt;&lt;br&gt;<strong>Dr. Michael Teitell</strong>&lt;br&gt;UCLA Jonsson Comprehensive Cancer Center</td>
</tr>
<tr>
<td>10:00 am</td>
<td><strong>Best Practices in Cell Therapy/CAR T</strong>&lt;br&gt;The FDA granted its first approvals for CAR T-cell therapy in 2017. In these early days of cellular therapy and other forms of adoptive cell transfer, more cancer centers are stepping up their efforts in the field. Among the decisions being weighed are whether to develop cells in-house, procure them from commercial entities, or embrace a hybrid approach. Panelists will consider that issue as well as the nuts and bolts of developing a CAR T-cell therapy program, including intake and management issues, standard operating procedures, financial challenges, and regulatory requirements.&lt;br&gt;&lt;br&gt;<strong>Moderator: Dr. Joseph McGuirk</strong>&lt;br&gt;The University of Kansas Cancer Center&lt;br&gt;&lt;br&gt;<strong>Dr. Lihua Elizabeth Budde</strong>&lt;br&gt;City of Hope Comprehensive Cancer Center&lt;br&gt;&lt;br&gt;<strong>Dr. Stephan A. Grupp</strong>&lt;br&gt;Children’s Hospital of Philadelphia&lt;br&gt;&lt;br&gt;<strong>Mr. Richard P. Bondi</strong>&lt;br&gt;UPMC Hillman Cancer Center</td>
</tr>
<tr>
<td>11:00 am</td>
<td><strong>Update on the NCI Cancer Centers Program</strong>&lt;br&gt;This session provides an opportunity for an open dialogue with the director of the NCI Office of Cancer Centers about the requirements and funding of the CCSG.&lt;br&gt;&lt;br&gt;<strong>Dr. Henry P. Ciolino</strong>&lt;br&gt;National Cancer Institute</td>
</tr>
<tr>
<td>11:45 am</td>
<td><strong>Adjourn</strong></td>
</tr>
</tbody>
</table>

---

9:45 pm  Break

Program Subject to Change
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the CME Request for Credit Survey by November 5, 2018. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

- The evolution of the academic cancer center in the next decade
- The value of bi-directional partnerships from both the clinical and research perspective in the global cancer enterprise
- Strategies for promoting both the clinical and research perspective in the global cancer enterprise
- Models of care across cancer center networks which promote efforts to integrate treatment services into the community
- Best practices for assembling an external advisory board (EAB)
- Ways to collect and integrate data with an eye toward expanded information-sharing and improved care for the cancer patient

Continuing Medical Education

- Strategies for navigating the changing health care marketplace
- The value of sequencing based approaches in breast and lung cancers
- Progress of the AACI Clinical Research Initiative (CRI) over the last decade
- Programmatic models which enhance comprehensive patient support and care
- Compliance with the most current NCI CCSG guidelines
- The impact of matrix rigidity on gene expression by the multiplicity of cells in the tumor microenvironment
- Challenges and opportunities for collaboration among academia, government, and the private sector
- Various aspects of compliance with the NCI CCSG guidelines with a focus on comprehensiveness, training, and community engagement
- Developing a CAR T-cell therapy program with an emphasis on intake and management issues, standard operating procedures, and regulatory requirements
- NCI’s priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact 412-647-6111 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This transdisciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects. All attendees have a significant impact on cancer research and patient care.

Attendees may include:
- Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical staff
- Leaders from industry and government agencies as well as those of cancer research and advocacy organizations
- Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, and psychologists
- Social workers, cancer communication specialists, public health leaders, and faculty members who focus on cancer

Target Audience
This transdisciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects. All attendees have a significant impact on cancer research and patient care.

Attendees may include:
- Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical staff
- Leaders from industry and government agencies as well as those of cancer research and advocacy organizations
- Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, and psychologists
- Social workers, cancer communication specialists, public health leaders, and faculty members who focus on cancer

14 Program Subject to Change

15
2018 AACI Distinguished Scientist Award

Dr. Charles M. Perou
UNC Lineberger Comprehensive Cancer Center

Charles M. Perou, PhD, is the May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger Comprehensive Cancer Center. He is also the faculty director of UNC Lineberger’s Bioinformatics Group, co-director of its Breast Cancer Research Program, and a professor in its Genetics and Pathology & Laboratory Medicine departments. His research interests span the disciplines of cancer biology, genomics, genetics, bioinformatics, statistics, systems biology, and the treatment of cancer patients in the clinic.

AACI’s award recognizes Dr. Perou’s research accomplishments in the field of precision medicine and his groundbreaking research in the characterization of the diversity of human tumors. The clinical value of Dr. Perou’s work leading to the discovery of the intrinsic subtypes of breast cancer has profoundly impacted the treatment of patients with breast cancer worldwide. In addition, his lab has successfully created computational predictors of complex cancer phenotypes, which will ultimately have clinical application.

After the award presentation, Dr. Perou will deliver a talk focused on sequencing studies for gene expression analysis, specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers.

A faculty member at UNC since 2000, Dr. Perou has authored more than 330 peer-reviewed articles and has filed to protect five patents in the United States and Europe. He earned his bachelor’s degree in biology from Bates College, his doctorate in cell biology from University of Utah, and performed his postdoctoral work in the laboratory of Dr. David Botstein (then at Stanford University).

Previous AACI Distinguished Scientist honorees are Drs. Carl June, James Allison, Lewis Cantley, Tim Ley, Brian Druker, Lee Hartwell, Mary-Claire King, Janet Rowley, Stuart Schreiber, Bert Vogelstein, Robert Weinberg, and Irving Weissman.

2018 AACI Champion for Cures Award

Richard and Susan Rogel

The Association of American Cancer Institutes (AACI) has established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer and in inspiring others to do the same. The inaugural award will be presented to Richard and Susan Rogel in recognition of their $150 million gift to the University of Michigan Comprehensive Cancer Center, which was renamed Rogel Cancer Center in their honor.

The gift is the largest ever to Michigan Medicine and one of the largest in the University of Michigan’s history. It will support cancer research by funding endowed professorships, competitive research grants, and scholarships, and by establishing a collaborative network that will bring international experts to the University of Michigan for six to 12 months to develop innovative new projects.

Having contributed $188.5 million to at least 17 different areas across the University of Michigan, the Rogels are the second largest individual donors in university history. They made their first major gift in 1987.

The Rogels’ lives have been touched extensively by cancer. Mr. Rogel, a U-M alum, lost his father to pancreatic cancer. Both of Mrs. Rogel’s parents died of cancer, and her 50-year-old daughter, Ilene, died five years ago from an aggressive form of lung cancer.

The Rogels live in Avon, Colorado, and Scottsdale, Arizona. Mr. Rogel serves as president of the investing firm Tomay Inc. A native of New Jersey, he is the founder, former chairman, and CEO of the Preferred Provider Organization of Michigan, which was the first in the country of this type of health insurance plan. In the late 1990s, he sold it to Blue Cross Blue Shield of Michigan.
Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Complion
The need for efficiency and standardization in clinical research has never been greater. Lack of standardization, manual processes, and teams working in technology silos make study management a major challenge.

At Complion, we see massive opportunities for increased efficiency and productivity. Our goal is to transform an institution’s regulatory environment into one driven by standards and consistency. That’s why we developed the first 21 CFR Part 11 compliant Electronic Regulatory (eRegulatory) system designed specifically for clinical research sites.

Our purpose-built eRegulatory system for research sites and organizations aims to:
- Ensure comprehensive trial documentation, with fewer incomplete or missing documents
- Improve version control across teams to ensure all documents are up to date and in one location
- Standardize processes and automate workflows to ensure adherence to SOPs
- Identify quality metrics to inform operations and process improvements
- Achieve audit-readiness and 21 CFR 11 compliance

Florence
Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence eBinders is trusted by 3,000+ researchers for eRegulatory, eSource, and contract management, and Florence eHub is revolutionizing site-sponsor connectivity in a shared workspace for startup, monitoring, and quality control.

Forte
Forte provides clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems to unleash their research potential. With a strong belief in community collaboration and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support.

Twice a year at the Onsemble Conference, clinical research professionals meet in one location to add features and tools not possible with print, such as social media feeds, perspectives on important issues facing today’s cancer care professionals.

GuideStar Research
GuideStar Research works with hospitals, health systems, and academic medical centers around the country to build and support clinical research programs. From helping organizations develop or refine a clinical trial strategy to providing support for coverage analysis, regulatory start-up, contracts, budgets, and more, our experienced team helps to ensure optimal results for research programs.

Huron
Huron is a global consultancy that helps our clients drive growth, enhance performance, and sustain leadership in the markets they serve. We partner with them to develop strategies and implement solutions that enable the transformative change our clients need to own their future. Learn more at www.huronconsultinggroup.com.

M2Gen
M2Gen® is a health informatics solutions company focused on accelerating the discovery and development of personalized medicines. M2Gen partners with the nation’s leading cancer centers through the Oncology Research Information Exchange Network (ORIEN) to create a large, cancer focused data warehouse linking clinical and molecular data. Using this information, M2Gen helps biopharmaceutical companies address the greatest challenges in oncology drug development. Founded in 2006, M2Gen operates the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. Through ORIEN, cancer centers serve more patients by sharing and collaborating. To date, more than 250,000 Total Cancer Care® consented patients have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level. For more information, visit www.M2Gen.com.

Merck
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs, and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease, and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube, and LinkedIn.

OncLive
OncLive is the official website for the Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, and Oncology Nursing News. The mission of OncLive and these publications is to provide oncology professionals with the resources and information they need to provide the best patient care. OncLive is also home to the Peer Exchange and Insights video editorial series, which provides a unique opportunity to view lively discussions with authoritative insights, opinions, and perspectives on important issues facing today’s cancer care professionals.

We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds,
blogs, and live coverage from major oncology meetings. As we move ahead, we will continually look for new and better ways to get you oncology news as quickly and efficiently as possible. It is an exciting time for cancer research and treatment, and we look forward to being Your Link to Everything Oncology.

**Patient Resource**
Patient Resource's innovative, advanced patient education, navigation and reporting platform provides hospitals and cancer centers with the tools to guide and track each cancer patient from the first appointment, throughout treatment, and on to survivorship. Guides, uniquely developed for each patient, include specific diagnosis and treatment care plans. Our personal, one-to-one, patient app provides medication adherence set-up as well as tracking options for self-reported outcomes. The system itself includes powerful administrative reporting and cost analysis tools and offers process standardization for all clinics.

**PFS Clinical**
PFS Clinical is dedicated to helping research institutions improve the management of their clinical trials from study start-up to final payment. Our research administration experts and collaborative service lines—Initiate, Revenue Guard, and Boost Consulting—support institutions through the various stages of clinical trials. Based on the needs of your institution, Initiate teams provide on-demand study initiation services for contracts, budgets, coverage analyses, and CTMS calendar builds. With Revenue Guard, our experienced research billing specialists can manage your billing processes with services including financial tracking, reconciliation, and reporting, and claims review, allowing you to focus on patient outcomes. Boost Consultants collaborate with your team to improve your research programs through meaningful process redesign, CTMS implementation, org. chart and SOP development, and flexible education and training. If you’re looking for a partner to be an extension of your research team, look to PFS Clinical. For more information, please visit www.pfsclinical.com or email questions@pfsclinical.com.

**Society for Immunotherapy of Cancer**
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals across the globe dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC at sitcancer.org and follow us on Twitter, LinkedIn, Facebook, and YouTube.

**Takeda Oncology**
Takeda Oncology is dedicated to developing and delivering novel medicines to cancer patients worldwide through our science, innovation, and passion. Our legacy includes therapies for hematologic cancers and solid tumors, including lung cancer. We aspire to cure cancer.

**TransCelerate BioPharma Inc.**
TransCelerate BioPharma Inc. is a nonprofit organization dedicated to improving the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapeutics. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry and examine solutions for addressing common challenges.

TransCelerate brings together R&D leaders from biopharmaceutical companies, research sites, clinical research organizations, regulatory authorities, and patient-focused organizations to develop solutions to common drug development issues and drive efficiencies into the R&D process. TransCelerate is proud to lead a progressive agenda that advances innovation in R&D. In the coming years, we will continue to challenge ourselves and take on new initiatives that we believe will improve the investigator and patient experience, encourage data-sharing as appropriate, reduce cost and process inefficiencies, and improve quality.

**Velos**
Velos is the trusted, comprehensive clinical research management software company for cancer centers, academic medical centers, hospital chains, national health systems, and other clinical research organizations and sponsors in the U.S. and internationally. For over fifteen years, Velos’ core mission has been to facilitate efficiency, quality and compliance in the field of clinical research with a particular focus on research at cancer centers. Our experience and vision is that a comprehensive approach to addressing clinical research information needs can unlock a wealth of value in both productivity and medical discovery. Anchored by the flagship Velos eResearch CRMS, the Velos product line supports study and protocol management, electronic data capture, financial management, protocol review and IRBs, patient recruitment, drug accountability, biospecimen management, and more. The company enables its customers to organize across multiple sites and research collaborators, remain 21 CFR Part 11 compliant, and integrate with key third party systems. Velos is privately held with headquarters in Fremont, California. For more information, please visit www.velos.com.
## Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

### Disclosure of Financial Relationships

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Member Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yabroff</td>
<td>K. Robin</td>
<td>American Cancer Society</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Welch</td>
<td>Jack</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Walker</td>
<td>Jeff</td>
<td>City of Hope National Medical Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Terrano</td>
<td>Cindy</td>
<td>Moffitt Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Teitell</td>
<td>Michael</td>
<td>UCLA Jonsson Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Sharpless</td>
<td>Norman</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Sellers</td>
<td>Donna</td>
<td>Hollings Cancer Center, Medical University of South Carolina</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bertram</td>
<td>Michael</td>
<td>UAB Comprehensive Cancer Center, University of Alabama at Birmingham</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bhatia</td>
<td>Smita</td>
<td>UAB Comprehensive Cancer Center, University of Alabama at Birmingham</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bondi</td>
<td>Richard</td>
<td>UPMC Hillman Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Budde</td>
<td>Liliah</td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Czitrom</td>
<td>John</td>
<td>Robert H. Lurie Comprehensive Cancer Center, University of North Carolina at Aurora</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Epstein</td>
<td>Ronald</td>
<td>Wilmot Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Evers</td>
<td>B. Mark</td>
<td>UK Markey Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Falleron</td>
<td>Seanne</td>
<td>Masonic Cancer Center, University of Minnesota</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Frommer</td>
<td>Ross</td>
<td>Columbia University Irving Medical School</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Gerstein</td>
<td>Stanton</td>
<td>Case Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Gopal</td>
<td>Satish</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Goksy</td>
<td>David</td>
<td>UK Markey Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Grupp</td>
<td>Stephan</td>
<td>Children’s Hospital of Philadelphia</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Haisett</td>
<td>Lauren</td>
<td>Vanderbilt Ingram Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Henry</td>
<td>Dave</td>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Hildebrand</td>
<td>Fay</td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Hollecker</td>
<td>Jane</td>
<td>Association of American Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Holcombe</td>
<td>Randall</td>
<td>University of Hawaii Cancer Center, University of Hawaii at MInneapolis</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Jensen</td>
<td>Roy</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Johnson</td>
<td>Candace</td>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Kastan</td>
<td>Michael</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Knudsen</td>
<td>Karen</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee</td>
</tr>
<tr>
<td>Kupferman</td>
<td>Karen</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Le Repos</td>
<td>Michele</td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lee</td>
<td>Carrie</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lee</td>
<td>Kelvin</td>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Loehr</td>
<td>Patrick</td>
<td>Indiana University Melvin &amp; Bren Simon Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Mannion</td>
<td>Robert</td>
<td>Stephenson Cancer Center, University of Oklahoma</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>McFarland</td>
<td>Daniel</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>McGuirk</td>
<td>Joseph</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Moore</td>
<td>Malcolm</td>
<td>BC Cancer</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Namkan</td>
<td>Dan</td>
<td>Ministry of Health, Malawi</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Neligan</td>
<td>Melissa</td>
<td>UCLA Jonsson Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Patel</td>
<td>Judith</td>
<td>Robert H. Lurie Comprehensive Cancer Center, University of North Carolina at Aurora</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Paterno</td>
<td>Steven</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Peacock</td>
<td>Stuart</td>
<td>BC Cancer</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Perou</td>
<td>Charles</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Ratloff</td>
<td>Timothy</td>
<td>Purdue University Center for Cancer Research</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Robison</td>
<td>Paul</td>
<td>The Jackson Laboratory Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Rosen</td>
<td>Paul</td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Rosenblatt</td>
<td>Donald</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Salipo</td>
<td>Kari</td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Sellers</td>
<td>Thomas</td>
<td>Moffitt Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Sharpsk</td>
<td>Norman</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Sweetenham</td>
<td>John</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Teitel</td>
<td>Michael</td>
<td>UCLA Jonsson Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Terrano</td>
<td>Cindy</td>
<td>Moffitt Cancer Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Walker</td>
<td>Jeff</td>
<td>City of Hope National Medical Center</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Welsh</td>
<td>Jack</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Yabloff</td>
<td>K. Robin</td>
<td>American Cancer Society</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Zahorsky</td>
<td>Alex</td>
<td>Robert H. Lurie Comprehensive Cancer Center, University of North Carolina at Aurora</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
</tbody>
</table>

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers’ Bureau; H, Honoraria; O, Other.
CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Claimed Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday 9/30/18</td>
<td>1:00 – 2:00 pm</td>
<td>A 10-Year Outlook for Academic Cancer Centers</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:00 – 2:15 pm</td>
<td>New President’s Initiative</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:45 – 4:00 pm</td>
<td>Cancer is a Global Issue: Partnerships with the</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:00 – 6:00 pm</td>
<td>Developing World</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:00 – 8:45 am</td>
<td>Maximum Approved Credits for 9/30/18</td>
<td>4.5</td>
<td>TOTAL:</td>
</tr>
<tr>
<td></td>
<td>8:45 – 10:00 am</td>
<td>How to Get the Most Out of Your EAB</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:15 – 11:30 am</td>
<td>Big Data in Cancer Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:30 am – 12:30 pm</td>
<td>Cancer Health Economics</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:00 – 2:00 pm</td>
<td>Quantitative Medicine for Breast Cancer Patients</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:15 – 2:45 pm</td>
<td>AACI Clinical Research Initiative (CRI) Update</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:45 – 4:00 pm</td>
<td>Comprehensive Cancer Patient Support</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:15 – 5:30 pm</td>
<td>CCSG Nuts and Bolts (concurrent)</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5:15 – 6:15 pm</td>
<td>Tumor Microenvironment (concurrent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:00 – 8:45 am</td>
<td>Maximum Approved Credits for 10/1/18</td>
<td>7.25</td>
<td>TOTAL:</td>
</tr>
<tr>
<td></td>
<td>8:45 – 9:45 am</td>
<td>NCI Director’s Report</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00 – 11:00 am</td>
<td>Guidelines-Driven Review: Conveying</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:00 – 11:45 am</td>
<td>Comprehensiveness, Training, and Community</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00 – 11:45 am</td>
<td>Best Practices in Cell Therapy/CAR T</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:00 – 11:45 am</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:00 – 8:45 am</td>
<td>Maximum Approved Credits for 10/2/18</td>
<td>3.5</td>
<td>TOTAL:</td>
</tr>
<tr>
<td></td>
<td>8:45 – 9:45 am</td>
<td>Maximum CME Credits Approved</td>
<td>15.25</td>
<td>TOTAL:</td>
</tr>
</tbody>
</table>

Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Astellas
- AstraZeneca
- Cejka Executive Search
- Flatiron
- Foundation Medicine
- Genomic Health
- Huron Consulting Group
- Lilly
- Merck
- Novartis
- Pfizer

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Complion
- Forte
- Genentech
- Gilead
- Janssen Research & Development
- Lilly
- Merck
- Pfizer
- Takeda Oncology
- Velos

Support as of September 12, 2018
2019 Meetings — Save the Date

July 10-11, 2019 • Loews Chicago O'Hare Hotel

October 20-22, 2019 • Mayflower Hotel